US Dollar vs Yen

登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。

登録

ホーム
投資
株式
アメリカ
NYSE
Organon and Co (OGN)
Organon and Co (OGN) ニュース

OGN

Organon (OGN)

Organon and Co

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/12/23	20 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/12/19	21 : 30	Business Wire	Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference	NYSE:OGN	Organon and Co
2024/12/16	21 : 30	Business Wire	FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	NYSE:OGN	Organon and Co
2024/12/07	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/11/05	21 : 40	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/11/05	21 : 29	Business Wire	Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older	NYSE:OGN	Organon and Co
2024/11/01	21 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:OGN	Organon and Co
2024/10/31	21 : 40	Business Wire	米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理	NYSE:OGN	Organon and Co
2024/10/31	21 : 39	Business Wire	US-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)	NYSE:OGN	Organon and Co
2024/10/31	21 : 39	Business Wire	美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)	NYSE:OGN	Organon and Co
2024/10/31	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/10/31	20 : 30	Business Wire	Organon Reports Results for the Third Quarter Ended September 30, 2024	NYSE:OGN	Organon and Co
2024/10/31	13 : 02	Business Wire	La FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)	NYSE:OGN	Organon and Co
2024/10/30	19 : 00	Business Wire	US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)	NYSE:OGN	Organon and Co
2024/10/30	01 : 22	Business Wire	Organon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %	NYSE:OGN	Organon and Co
2024/10/30	01 : 22	Business Wire	オルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得	NYSE:OGN	Organon and Co
2024/10/30	01 : 22	Business Wire	Organon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %	NYSE:OGN	Organon and Co
2024/10/28	22 : 25	Business Wire	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NYSE:OGN	Organon and Co
2024/10/28	22 : 25	GlobeNewswire Inc.	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%	NYSE:OGN	Organon and Co
2024/10/09	20 : 30	Business Wire	Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024	NYSE:OGN	Organon and Co
2024/10/08	21 : 01	PR Newswire (Canada)	Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands	NYSE:OGN	Organon and Co
2024/10/08	21 : 01	PR Newswire (Canada)	Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établies	NYSE:OGN	Organon and Co
2024/10/01	04 : 26	Business Wire	パージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成	NYSE:OGN	Organon and Co
2024/10/01	01 : 17	Business Wire	Primärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreicht	NYSE:OGN	Organon and Co
2024/10/01	00 : 59	Business Wire	Critères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)	NYSE:OGN	Organon and Co
2024/09/30	19 : 00	Business Wire	Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11	NYSE:OGN	Organon and Co
2024/09/26	22 : 50	PR Newswire (Canada)	Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada	NYSE:OGN	Organon and Co
2024/09/26	22 : 49	PR Newswire (Canada)	Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au Canada	NYSE:OGN	Organon and Co
2024/09/24	05 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:OGN	Organon and Co
2024/09/20	03 : 30	Business Wire	オルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得	NYSE:OGN	Organon and Co

Showing the most relevant articles for your search:NYSE:OGN

1 2 3 4 5 6 7 8 9 10 次へ >>

Verizon Communications

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約